HER2/EGFR in Cancer Research
HER2/EGFR in Cancer Research is a research topic within Oncology. Science Explorer counts 34k research works in it since 1950. 20.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression.
- HER2
- breast cancer
- trastuzumab
- EGFR
- monoclonal antibody
- chemotherapy
- metastatic
- receptor tyrosine kinases
- neuregulin 1
- ADAM metalloproteinases
- Research works
- 34k fractional, since 1950
- In the world top 10%
- 6.8k per year above
- Top-10% rate
- 20.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -4% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead HER2/EGFR in Cancer Research research?
By volume, the United States and China publish the most (1.5k and 1.3k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.5k works
- 2 China 1.3k works
- 3 Japan 324 works
- 4 India 271 works
- 5 Italy 238 works
- 6 Germany 227 works
- 7 United Kingdom 192 works
- 8 Spain 180 works
- 9 South Korea 180 works
- 10 France 170 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead HER2/EGFR in Cancer Research research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most HER2/EGFR in Cancer Research research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Memorial Sloan Kettering Cancer Center.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 57 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 50 works
- 3 Memorial Sloan Kettering Cancer CenterUnited States 41 works
- 4 University of North Carolina at Chapel HillUnited States 32 works
- 5 Dana-Farber Cancer InstituteUnited States 29 works
- 6 Fudan University Shanghai Cancer CenterChina 29 works
- 7 Sun Yat-sen UniversityChina 28 works
- 8 Harvard UniversityUnited States 23 works
- 9 Sichuan UniversityChina 21 works
- 10 Peking UniversityChina 21 works
Who are the leading researchers in HER2/EGFR in Cancer Research?
The most-cited researchers publishing on HER2/EGFR in Cancer Research include Dirk Schadendorf, Charles M. Perou and Hagop M. Kantarjian.
- 1 Dirk Schadendorf Germany 4.4k citations
- 2 Charles M. Perou United States 4.2k citations
- 3 Hagop M. Kantarjian United States 4k citations
- 4 Gordon B. Mills United States 3.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is HER2/EGFR in Cancer Research research done?
The largest centres of HER2/EGFR in Cancer Research research in 2022–2025 are Beijing (China), Shanghai (China), New York (United States) and Seoul (South Korea).
Largest cities, 2022–2025
Where is the best place to study HER2/EGFR in Cancer Research?
Among universities, judged by research, Shanghai Medical College of Fudan University, Chinese Academy of Medical Sciences & Peking Union Medical College and University of Milan score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Shanghai Medical College of Fudan UniversityChina | 56.8 | 42.2% | 18.8× | 9 | +12.6% |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 53.9 | 17.6% | 8.9× | 50 | -13.1% |
| 3 | University of MilanItaly | 51.3 | 48.5% | 3.9× | 15 | +16.2% |
| 4 | Harvard UniversityUnited States | 46.6 | 40.1% | 3.1× | 23 | -22.8% |
| 5 | China Pharmaceutical UniversityChina | 45.9 | 24.8% | 9.1× | 11 | +27.3% |
| 6 | University of UlsanSouth Korea | 43.2 | 28.7% | 7.8× | 8 | +42.0% |
| 7 | Harbin Medical UniversityChina | 41.0 | 19.5% | 9.9× | 12 | -38.2% |
| 8 | Hebei Medical UniversityChina | 39.2 | 12.9% | 9.2× | 11 | +48.3% |
| 9 | Sichuan UniversityChina | 38.7 | 32.5% | 2.2× | 21 | +30.0% |
| 10 | Sun Yat-sen UniversityChina | 38.6 | 23.2% | 3.0× | 28 | +32.9% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is HER2/EGFR in Cancer Research research growing?
Output in 2018–2022 was 4% lower than in 2013–2017, peaking in 2025. The fastest-growing topics are HER2/EGFR in Cancer Research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.